A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Sponsors ArQule
- 21 Nov 2017 According to an ArQule media release, the company announced dosing of the initial four patients in this trial.
- 09 Nov 2017 According to an ArQule media release, an interim analysis will be preformed after the first 40 patients have been enrolled and evaluated for response.
- 16 Oct 2017 According to an ArQule media release, company anticipates to complete enrollment of patients needed to perform the interim analysis through the first part of 2019.